Live·Open questions in longevity research
All news
Biotech fundingLongevity researchIndustry & policy

Aging research lacks ideas backed by rigorous theory and strong data, says researcher Max Unfried; investor Karl Pfleger and biologist Martin Borch Jensen disagree

18 November 2026· 261118004

Aging research lacks ideas backed by rigorous theory and strong data, says researcher Max Unfried; investor Karl Pfleger and biologist Martin Borch Jensen disagree

On November 16, Max Unfried wrote on X that capital in longevity research is being allocated appropriately. Pfleger disagreed: in his experience, around three-quarters of companies trying to bring ideas backed by theory and strong data to market fail because they lack funding. Jensen wrote that he could easily put 50 million dollars toward good research.

Unfried set out his argument in the original post:

“The real bottleneck is the availability of ideas solid enough to fund, backed by rigorous theory and strong data. Most projects, both academic and commercial, have neither, so capital is actually being allocated appropriately.”

Adam Gries, founder of Vitalism, a movement against aging and death, replied that funding can generate ideas: people with good ideas lack the money to devote time to them and run preliminary experiments, so their work advances in small steps. Unfried countered that many ideas in longevity biology rest on intuition: ask three questions about almost any topic, and people answer, “We don't know.” In his view, most studies that screen compounds in model organisms such as mice and worms to see what works involve very little deep thinking. He supports funding experiments that at least provide answers, allowing researchers to reach the fourth question.

Gries asked whether it would be money well spent to give each of a hundred very smart people a year to develop ideas and several million to test them. Unfried conceded that this would be better than the current academic model, provided they were “not allowed to do anything else” during that year and focused solely on thinking through the most consequential experiment.

Karl Pfleger, an investor in rejuvenation startups, replied that funding drives the basic research that produces data, theories, and ideas for interventions. He then described companies that meet Unfried's criterion of having theory and strong data:

“Around three-quarters of the companies I see trying to put ideas backed by theory and strong data into practice, bring them to market, and scale them up fail because they lack money. They aren't failing because the biology is wrong and the data turned out poorly.”

He had also discussed the funding shortage in September: LEV Foundation had completed one experiment combining therapies and was still raising money for a second.

Martin Borch Jensen, founder of Norn Group, which awards grants for longevity research, wrote on November 17 that he could easily put 50 million dollars toward good research this year. Funding is one of several bottlenecks, he added, and there is plenty of good research to fund, although there is more poor research.

Unfried replied to Jensen that 50 million would be enough to launch several biotech companies or fund a dozen laboratories for a multiyear project. Such projects exist, he said, but discussions of underfunding in the field usually concern larger sums. He used the budget of the US National Cancer Institute (NCI) to illustrate the scale he meant:

“Suppose aging research received a quarter of the NCI's annual budget, or around 1,8 billion dollars. I think it would be difficult to spend that on rigorous science. Spending it on academic science in its current form would probably be easy.”

The institute's budget for fiscal year 2026 is 7,35 billion dollars, a quarter of which is 1,84 billion.

Gries's scenario, with several million for each of a hundred people, would cost hundreds of millions: more than Jensen's 50 million and less than Unfried's 1,8 billion.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#longevity-funding#aging-research#research-grants#capital-allocation#science-policy